Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer

Clinical and Experimental Medicine

Volumn 14, Issue 3, 2014, Pages 345-353

  Suh, Dong Hoon ^a,b   Kim, Min A ^a   Kim, Haeryoung ^b   Kim, Mi Kyung ^a   Kim, Hee Seung ^a   Chung, Hyun Hoon ^a   Kim, Yong Beom ^b   Song, Yong Sang ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Drug resistance; Hexokinase; Immunohistochemistry; Ovarian cancer; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; HEXOKINASE;

ADULT; AGED; BIOSYNTHESIS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; HEXOKINASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84905095742     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-013-0250-9     Document Type: Article

References (40)

1. Szegezdi E, Cahill S, Meyer M, O'Dwyer M, Samali A (2006) TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br J Cancer 94(3):398-406. doi:10.1038/sj.bjc.6602954 (Pubitemid 43237564)
2. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 27(16):2686-2691. doi:10.1200/JCO.2008.19.2963
3. Itamochi H (2010) Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem 1(7):209-220. doi:10.4331/wjbc.v1.i7.209
4. Suh DH, Kim JW, Kim K, Kang SB (2010) Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol 21(4):209-218. doi:10.3802/jgo. 2010.21.4.209
5. Suh DH, Kim MK, No JH, Chung HH, Song YS (2011) Metabolic approaches to overcoming chemoresistance in ovarian cancer. Ann N Y Acad Sci 1229:53-60. doi:10.1111/j.1749-6632.2011.06095.x
6. Fabian C, Koetz L, Favaro E, Indraccolo S, Mueller-Klieser W, Sattler UG (2012) Protein profiles in human ovarian cancer cell lines correspond to their metabolic activity and to metabolic profiles of respective tumor xenografts. FEBS J 279(5):882-891. doi:10.1111/j.1742-4658.2012.08479.x
7. Shulga N, Wilson-Smith R, Pastorino JG (2009) Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle 8(20):3355-3364
8. Pedersen PL (2007) Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg effect", i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39(3):211-222. doi:10.1007/s10863-007-9094-x
9. Pastorino JG, Hoek JB (2008) Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr 40(3):171-182. doi:10.1007/s10863-008-9148-8
10. Kim EE (2004) Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology. Int J Gynecol Cancer 14(1):12-22
11. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg effect" and a pivotal target for effective therapy. Semin Cancer Biol 19(1):17-24. doi:10.1016/j.semcancer.2008.11.006
12. Kitajima K, Suzuki K, Senda M, Kita M, Nakamoto Y, Onishi Y, Maeda T, Yoshikawa T, Ohno Y, Sugimura K (2011) FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med Commun 32(7):549-553. doi:10.1097/MNM.0b013e328345b339
13. Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D (2009) The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 50(Suppl 1):64S-73S. doi:10.2967/jnumed.108.057257
14. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC (2008) Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 19(4):1045-1053
15. Lyshchik A, Higashi T, Hara T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, Saga T, Togashi K (2007) Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Investig 25(3):154-162. doi:10.1080/07357900701208931 (Pubitemid 47164858)
16. Rho M, Kim J, Jee CD, Lee YM, Lee HE, Kim MA, Lee HS, Kim WH (2007) Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res 27(1A):251-258 (Pubitemid 46363339)
17. Smith TA (2000) Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 57(2):170-178
18. Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K (2008) Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci 99(2):260-266. doi:10.1111/j.1349-7006.2007.00683.x (Pubitemid 351228478)
19. Gong L, Cui Z, Chen P, Han H, Peng J, Leng X (2011) Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II. Med Oncol. doi:10.1007/s12032-011-9841-z
20. Neary CL, Pastorino JG (2010) Nucleocytoplasmic shuttling of hexokinase II in a cancer cell. Biochem Biophys Res Commun 394(4):1075-1081. doi:10.1016/j.bbrc.2010.03.129
21. Milane L, Duan Z, Amiji M (2011) Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int 11:3. doi:10.1186/1475-2867-11-3
22. Ahn KJ, Hwang HS, Park JH, Bang SH, Kang WJ, Yun M, Lee JD (2009) Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines. J Nucl Med 50(9):1525-1532
23. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, Guha A (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208(2):313-326. doi:10.1084/jem.20101470
24. Hamada K, Tomita Y, Qiu Y, Zhang B, Ueda T, Myoui A, Higuchi I, Yoshikawa H, Aozasa K, Hatazawa J (2008) 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Ann Nucl Med 22(8):699-705. doi:10.1007/s12149-008-0173-9
25. Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, Doi R, Hosotani R, Imamura M, Konishi J (2002) Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 43(2):173-180 (Pubitemid 34151039)
26. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25(34):4777-4786. doi:10.1038/sj.onc.1209603 (Pubitemid 44187625)
27. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH (2000) Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 7(12):1166-1173. doi:10.1038/sj.cdd.4400783 (Pubitemid 32042223)
28. Kim JW, Gao P, Dang CV (2007) Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 26(2):291-298. doi:10.1007/s10555-007-9060-4 (Pubitemid 47103157)
29. Lim HY, Ho QS, Low J, Choolani M, Wong KP (2011) Respiratory competent mitochondria in human ovarian and peritoneal cancer. Mitochondrion 11(3):437-443. doi:10.1016/j.mito.2010.12.015
30. Karantanis D, Allen-Auerbach M, Czernin J (2012) Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clin Nucl Med 37(1):49-53. doi:10.1097/RLU.0b013e3182291e03
31. Ozcan A, Deveci MS, Oztas E, Dede M, Yenen MC, Korgun ET, Gunhan O (2005) Prognostic value of GLUT-1 expression in ovarian surface epithelial tumors: a morphometric study. Anal Quant Cytol Histol 27(4):181-186 (Pubitemid 41233493)
32. Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Shih IM, Bristow RE (2007) Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gynecol Cancer 17(3):601-606. doi:10.1111/j.1525-1438.2007. 00820.x (Pubitemid 46743993)
33. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM (2008) Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108(3):510-514. doi:10.1016/j.ygyno.2007.11.013
34. Suh DH, Kim HS, Chung HH, Kim JW, Park NH, Song YS, Kang SB (2012) Body mass index and survival in patients with epithelial ovarian cancer. J Obstet Gynaecol Res 38(1):70-76. doi:10.1111/j.1447-0756.2011.01628.x
35. Lee HP (2007) Annual report of gynecologic cancer registry program in Korea for 2004. Korean J Obstet Gynecol 50(1):28-78
36. Jawhar NM (2009) Tissue microarray: a rapidly evolving diagnostic and research tool. Ann Saudi Med 29(2):123-127
37. Shergill IS, Shergill NK, Arya M, Patel HR (2004) Tissue microarrays: a current medical research tool. Curr Med Res Opin 20(5):707-712. doi:10.1185/030079904125003412 (Pubitemid 38685016)
38. El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C (2011) Sugar-free approaches to cancer cell killing. Oncogene 30(3):253-264. doi:10.1038/onc.2010.466
39. Pathania D, Millard M, Neamati N (2009) Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 61(14):1250-1275. doi:10.1016/j.addr.2009.05.010
40. Milane L, Duan Z, Amiji M (2011) Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One 6(9):e24075. doi:10.1371/journal.pone. 0024075